News
COVID and med ed cost: Are future docs paying more for less?
October 30, 2020
“Am I just going to end up doing most of my year online, and what does that look like for my future patients?”
News
Two COVID-19 outpatient antibody drugs show encouraging results
October 30, 2020
Two COVID-19 antibody treatments, one developed by Regeneron and the other by Eli Lilly, show promise in the outpatient setting.
News
Skin symptoms common in COVID-19 ‘long-haulers’
October 30, 2020
Many studies have reported dermatologic effects of COVID-19 infection, but information was lacking about duration.
News
COVID-19 diagnosed on CTA scan in stroke patients
October 29, 2020
“As part of the stroke evaluation workup process, we were able to diagnose COVID-19 at the same time at no extra cost or additional workload.”
News
More mask wearing could save 130,000 US lives by end of February
October 29, 2020
“Case numbers are climbing in the US, and without further intervention, there will be a significant number of deaths over the coming months.”
News
Chinese American families suffer discrimination related to COVID-19
October 29, 2020
In a sample of Chinese American parents and children, reports of racial discrimination during the pandemic were common.
![1]()
News
COVID frontline physicians afraid to seek mental health care
October 29, 2020
“The pandemic emphatically underscores our need to change the status quo when it comes to physicians’ mental health,” said Dr. Mark Rosenberg.
News
Consensus guidelines address inpatient diabetes technology
October 29, 2020
The comprehensive document aimed at clinicians, hospitals, and researchers covers use of both continuous glucose monitors and automated insulin dosing systems in the hospital setting.
News
Tocilizumab stumbles as COVID-19 treatment, narrow role possible
October 28, 2020
Three randomized controlled trials showed that the drug either had no benefit or only a modest one, contradicting a large retrospective study.
News
Lilly stops antibody trial in hospitalized COVID-19 patients, other trials continue
October 28, 2020
Eli Lilly announced it will halt its ACTIV-3 trial evaluating the antibody bamlanivimab in combination with remdesivir for people hospitalized with COVID-19.
